CAMP4 Therapeutics (CAMP) Fundamentals 2026 — Revenue Analysis | SniperIQ
CAMP4 Therapeutics (CAMP) is a US-listed Healthcare company in Biotechnology with a market capitalization of $66M, trading at
CAMP4 Therapeutics (CAMP) has a market capitalization of approximately $66M, trading at
CAMP4 Therapeutics's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 5.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
CAMP4 Therapeutics runs a net profit margin of -2193.7%, a gross margin of 76.2%, and an operating margin of -1322.6%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
CAMP4 Therapeutics reported revenue of
CAMP4 Therapeutics does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
CAMP4 Therapeutics carries a debt-to-equity ratio of 0.07x and a current ratio of 6.15x, with a market beta of 0.10. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For CAMP4 Therapeutics (CAMP) the key facts are: market cap $66M, revenue
Get CAMP4 Therapeutics's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.